Pharmacological topics of bone metabolism: Recent advances in pharmacological management of osteoporosis

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 530-535

  Suzuki, Atsushi ^a   Sekiguchi, Sahoko ^a   Asano, Shogo ^a   Itoh, Mitsuyasu ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Antiresorptive agent; Bone formation; Bone metabolism; Bone turnover; Fracture risk; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PRASTERONE; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SALCATONIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STERYL SULFATASE; STRONTIUM RANELATE; TAMOXIFEN; VITAMIN D DERIVATIVE; VITAMIN K GROUP;

AGING; ANDROPAUSE; AUSTRALIA; BONE DENSITY; BONE METABOLISM; BONE NECROSIS; BONE TURNOVER; CONFERENCE PAPER; DEVELOPED COUNTRY; DRUG INDICATION; EUROPE; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; JAPAN; JAW OSTEONECROSIS; MENOPAUSE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; UNITED STATES; VERTEBRA FRACTURE;

EID: 42349096158     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FM0070218     Document Type: Conference Paper

References (40)

1. Prevention and Management of Osteoporosis. Report of a WHO scientific group. WHO Technical Report Series 921. 2003.
2. Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, et al. Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol. 1995;24:1171-1177.
3. Fujiwara S, Kasagi F, Yamada M, Kodama K. Risk factors for hip fracture in a Japanese cohort. J Bone Miner Res. 1997;12:998-1004.
4. Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res. 2005;20:898-905.
5. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91:1621-1634.
6. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891-2897.
7. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
8. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.
9. Traish A, Guay AT, Spark RF. the Testosterone Therapy in Women Study Group. Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women Misguided? A Commentary. J Sex Med. 2007;4:1223-1235.
10. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab. 2006;91:3697-3710.
11. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab. 2006;91:2986-2993.
12. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, et al. Peptide antagonists of the human estrogen receptor. Science. 1999;285:744-746.
13. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
14. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727-2741.
15. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Eng J Med. 2006;355:125-137.
16. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148:363-373.
17. Rosen J, Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact. 2002;2:222-224.
18. Eastell R. Pathogenesis of postmenopausal osteoporosis. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. American Society for Bone and Mineral Research; 2006. p. 259-262.
19. Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L, et al. Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev. 2001;4:CD003376.
20. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-516.
21. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:517-523.
22. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
23. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.
24. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-1322.
25. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838-1846.
26. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
27. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
28. Muñoz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004;3:117-132.
29. Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int. 2005;16:1281-1290.
30. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther. 2006;6:1041-1050.
31. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al, Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22:1832-1841.
32. Deaton DN, Tavares FX. Design of cathepsin K inhibitors for osteoporosis. Curr Top Med Chem. 2005;5:1639-1675.
33. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
34. Tournis S, Economopoulos D, Lyritis GP. Strontium ranelate: a novel treatment in postmenopausal osteoporosis. Ann N Y Acad Sci. 2006;1092:403-407.
35. Pi M, Quarles LD. A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res. 2004;19:862-869.
36. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370:657-666.
37. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
38. Ono Y, Suzuki A, Kotake M, Zhang X, Nishiwaki-Yasuda K, Ishiwata Y, et al. Seasonal changes of serum 25-hydroxyvitamin D and intact parathyroid hormone levels in a normal Japanese population. J Bone Miner Metab. 2005;23:147-151.
39. Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005;90:5031-5036.
40. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and the prevention of fractures: systemic review and meta-analysis of randomized controlled trials. Arch Int Med. 2006;166:1256-1261.